Clinical Trial

Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Study acronym: STAR-02
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the initial efficacy and safety of neoadjuvant low-dose interval radiotherapy combined with tirelizumab and SOX chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-05.
Status change: Not Yet Recruiting → Recruiting 2026-04-24
Trial Details
NCT Number NCT06766578
Lead Sponsor Shandong Provincial Hospital
Conditions Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment 32 participants
Start Date 2024-12-30
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-29